Skip to main content

Advertisement

Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup

Fig. 1

Comparison of CSF sTREM2 levels between groups and subgroups. Graphs show how CSF sTREM2 levels differ across (a) control and dementia (overall FTD, containing bvFTD and PPA) groups; (b) controls and clinical subgroups; (c) controls and genetic subgroups; and (d) controls and CSF biomarker-defined dementia subgroups (pathological subgroups). AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. Horizontal bars show mean CSF sTREM2 levels and upper and lower 95% CIs for each group. *P < 0.05, **P < 0.01. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, bvFTD Behavioural variant frontotemporal dementia, C9orf72 Chromosome 9 open reading frame 72 gene, FTD Frontotemporal dementia, CSF Cerebrospinal fluid, GRN Progranulin gene, lvPPA Logopenic variant primary progressive aphasia, MAPT Microtubule-associated protein tau gene, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia, T-tau Total tau

Back to article page